Quantitative susceptibility mapping of the motor cortex in amyotrophic lateral sclerosis and primary lateral sclerosis.
暂无分享,去创建一个
Tian Liu | Yi Wang | Ajay Gupta | Mona Shahbazi | Yi Wang | Tian Liu | A. Tsiouris | Ajay Gupta | A. Schweitzer | A. Shtilbans | S. Seedial | D. Lange | Andrew D Schweitzer | Alexander Shtilbans | Dale Lange | A John Tsiouris | Karen Zheng | Stephen Seedial | Karen S Zheng | Mona Shahbazi
[1] J. Connor,et al. Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.
[2] J. Cedarbaum,et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.
[3] P. Gordon. Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials. , 2013, Aging and disease.
[4] V. Meininger,et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.
[5] A. Ignjatović,et al. Brain iron MRI: A biomarker for amyotrophic lateral sclerosis , 2013, Journal of magnetic resonance imaging : JMRI.
[6] M. Cudkowicz,et al. Serum Ferritin and Metal Levels as Risk Factors for Amyotrophic Lateral Sclerosis , 2008, The open neurology journal.
[7] Yi Wang,et al. Morphology enabled dipole inversion for quantitative susceptibility mapping using structural consistency between the magnitude image and the susceptibility map , 2012, NeuroImage.
[8] J. Connor,et al. Plasma biomarkers associated with ALS and their relationship to iron homeostasis , 2010, Muscle & nerve.
[9] Robert G. Miller,et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2012, The Cochrane database of systematic reviews.
[10] M Takahashi,et al. T2 shortening in the motor cortex: effect of aging and cerebrovascular diseases. , 1996, Radiology.
[11] Wei Wang,et al. Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease. , 2009, Radiology.
[12] Adam B. Cohen,et al. Quality improvement in neurology: Amyotrophic lateral sclerosis quality measures , 2013, Neurology.
[13] J. Statland,et al. Primary lateral sclerosis , 2007, Muscle & nerve.
[14] Ferdinand Schweser,et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study , 2012, NeuroImage.
[15] P. Leigh,et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.
[16] Johannes B Reitsma,et al. Case-control and two-gate designs in diagnostic accuracy studies. , 2005, Clinical chemistry.
[17] M. Gaweł,et al. Amyotrophic lateral sclerosis: correlation of clinical and MR imaging findings. , 1995, Radiology.
[18] S. Riad.,et al. High T2 Signal in Primary Lateral Sclerosis Supports the Topographic Distribution of Fibers in the Corpus Callosum: Assessing Disease in the Primary Motor Segment , 2011, American Journal of Neuroradiology.
[19] M. Tartaglia,et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. , 2007, Archives of neurology.
[20] K. Morrison,et al. Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients , 2008, Journal of Neurology.
[21] S. Stuckey,et al. Hyperintensity of the precentral gyral subcortical white matter and hypointensity of the precentral gyrus on fluid-attenuated inversion recovery: variation with age and implications for the diagnosis of amyotrophic lateral sclerosis. , 2007, AJNR. American journal of neuroradiology.
[22] O. Hardiman,et al. Amyotrophic lateral sclerosis , 2011, The Lancet.
[23] M. Swash,et al. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[24] M. Argyropoulou,et al. T2 relaxation rate of basal ganglia and cortex in patients with β-thalassaemia major , 2001 .
[25] M. Beal,et al. The diagnostic utility of FLAIR imaging in clinically verified amyotrophic lateral sclerosis , 2003, Journal of magnetic resonance imaging : JMRI.
[26] Arzu Arslan,et al. Perirolandic cortex of the normal brain: low signal intensity on turbo FLAIR MR images. , 2003, Radiology.
[27] K. Ohtomo,et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. , 1993, Radiology.
[28] Jeff H. Duyn,et al. Iron Accumulation in Deep Cortical Layers Accounts for MRI Signal Abnormalities in ALS: Correlating 7 Tesla MRI and Pathology , 2012, PloS one.
[29] Yi Wang,et al. Morphology enabled dipole inversion (MEDI) from a single‐angle acquisition: Comparison with COSMOS in human brain imaging , 2011, Magnetic resonance in medicine.
[30] M. Arbesman,et al. Systematic review of the effectiveness of occupational therapy-related interventions for people with amyotrophic lateral sclerosis. , 2014, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.
[31] M Takahashi,et al. T2 shortening in the visual cortex: effect of aging and cerebrovascular disease. , 1997, AJNR. American journal of neuroradiology.
[32] Pascal Spincemaille,et al. Nonlinear formulation of the magnetic field to source relationship for robust quantitative susceptibility mapping , 2013, Magnetic resonance in medicine.